Abiopharma

Corrective report for a presentation to the capital market - June 2026 - typographical error in the EBITDA data on page 25

Financial Statements and Related Announcement: Full Yearly Results

NUBURU Anticipates Stockholders Equity to Materially Exceed NYSE American Requirement Based on Preliminary May 31 Review

QT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week

Performance Shipping Inc. Announces Approval of Amendments Making Its Bonds Senior Unsecured

SUNTEX ENTERPRISES APPOINTS FORMER SPACEX EXECUTIVE TECHNOLOGY SPECIALIST VINCENT ORNELAS TO BOARD OF DIRECTORS

Bonus Issue/ Capitalisation Issue :

Clinical trial NCT05629624 updates: 1. status: UNKNOWN → COMPLETED 2. completion date: 2024-08-01 → 2025-01-31 3. primary completion date: 2024-08-01 → 2025-01-31 4. enrollment: 280 → 297 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT05377996 updates: 1. completion date: 2027-05-01 → 2027-12-01 2. primary completion date: 2026-12-01 → 2027-02-01 3. enrollment: 319 → 360 participants

Clinical trial NCT06627647 updates: 1. completion date: 2030-03-25 → 2030-11-18 2. primary completion date: 2029-05-10 → 2030-11-18